Top

Published in:

01-02-2013 | Review Article

Evolving Management of Pediatric Pulmonary Arterial Hypertension: Impact of Phosphodiesterase Inhibitors

Authors: Andrew James Wardle, Robert M. R. Tulloh

Published in: Pediatric Cardiology | Issue 2/2013

Abstract

The treatment of pulmonary arterial hypertension (PAH) has undergone significant change in recent years, improving both quality of life and survival for patients. One of the principal new agents is sildenafil, a phosphodiesterase-V inhibitor with great PAH efficacy. Its success has led to consideration of other phosphodiesterase inhibitors not yet licensed for pediatric PAH including tadalafil and vardenafil, among others. This article summarizes the evidence base for phosphodiesterase inhibitors used to ameliorate pediatric PAH pathology and associated symptoms. It also analyzes their suitability for contemporary practice with the aim of clarifying and helping to direct regimens that produce improved patient outcomes.

Atz AM, Lefler AK, Fairbrother DL et al (2002) Sildenafil augments the effect of inhaled nitric oxide for postoperative pulmonary hypertensive crises. J Thorac Cardiovasc Surg 124:628–629PubMedCrossRef

Badesch DB, Champion HC, Sanchez MA et al (2009) Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 54(Suppl 1):S55–S66PubMedCrossRef

Barst RJ, Oudiz RJ, Beardsworth A et al (2011) Pulmonary arterial hypertension and response to tadalafil (PHIRST) study group: tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension. J Heart Lung Transplant 30:632–643PubMedCrossRef

Barst RJ, Dunbar I, Gaitan G et al (2012) A randomised double-blind placebo-controlled dose-ranging study of oral sildenfail citrate in treatment naive children with pulmonary arterial hypertension. Circulation 125:324–334PubMedCrossRef

Barst RJ, McGoon MD, Elliott CG et al (2012) Childhood pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management. Circulation 125:113–122PubMedCrossRef

Bassler D, Choong K, McNamara P et al (2006) Neonatal persistent pulmonary hypertension treated with milrinone: four case reports. Biol Neonate 89:1–5PubMedCrossRef

Berger RM, Beghetti M, Humpl T et al (2012) Clinical features of paediatric pulmonary hypertension: a registry study. Lancet 379:537–546PubMedCrossRef

Carroll WD, Dhillon R (2003) Sildenafil as a treatment for pulmonary hypertension. Arch Dis Child 88:827–828PubMedCrossRef

Della Torre F, Della Torre E, Di Berardino F (2005) Sildenafil in pulmonary hypertension. Sarcoidosis Vasc Diffuse Lung Dis 22:78–79PubMed

10.

Derynck R, Zhang YE (2003) Smad-dependent and Smad-independent pathways in TGF family signalling. Nature 425:577–584PubMedCrossRef

11.

Fraisse A, Jais X, Schleich JM et al (2010) Characteristics and prospective 2-year follow-up of children with pulmonary arterial hypertension in France. Arch Cardiovasc Dis 103:66–74PubMedCrossRef

12.

Galie JN, Brundage BH, Ghofrani H et al (2009) Tadalafil therapy for pulmonary arterial hypertension. Pulmonary arterial hypertension and response to tadalafil (PHIRST) study group. Circulation 119:2894–2903PubMedCrossRef

13.

Hawkins A, Langton-Hewer S, Henderson J et al (2011) Management of pulmonary hypertension in down syndrome. Eur J Pediatr 170:915–921PubMedCrossRef

14.

Humpl T, Reyes JT, Holtby H et al (2005) Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension: twelve-month clinical trial of a single drug, open-label, pilot study. Circulation 111:3274–3280PubMedCrossRef

15.

Jing ZC, Yu ZX, Shen JY et al (2011) Vardenafil in pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study. Efficacy and safety of vardenafil in the treatment of pulmonary arterial hypertension (evaluation) study group. Am J Respir Crit Care Med 183:1723–1729PubMedCrossRef

16.

Karasu-Minareci E, Ozbudak I, Ozbillim G, et al (2012) Acute effects of vardenafil on pulmonary artery responsiveness in pulmonary hypertension. Sci World J 2012. doi:10.1100/2012/718279

17.

Karatza AA, Bush A, Magee AG (2005) Safety with pulmonary hypertension. Int J Cardiol 100:267–273PubMedCrossRef

18.

Lowe G, Costabile R (2012) 10-year analysis of adverse event reports to the food and drug administration for phosphodiesterase type-5 inhibitors. J Sex Med 9:265–270PubMedCrossRef

19.

Moledina S, Hislop AA, Foster H et al (2010) Childhood idiopathic pulmonary arterial hypertension: a national cohort study. Heart 96:1401–1406PubMedCrossRef

20.

Namachivayam P, Theilen U, Butt WW et al (2006) Sildenafil prevents rebound pulmonary hypertension after withdrawal of nitric oxide in children. Am J Respir Crit Care Med 174:1042–1047PubMedCrossRef

21.

Simmoneau G, Robbins IM, Beghetti M et al (2009) Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 54:S43–S54CrossRef

22.

Simonneau G, Rubin LJ, Galie N et al (2008) Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med 149:521–530PubMed

23.

Spring RM, Ulrich S, Huber LC et al (2008) Sildenafil for pulmonary hypertension: dose-dependent improvement in exercise performance. Pulm Pharmacol Ther 21:516–521PubMedCrossRef

24.

Sun X, Li Z, Liu Y et al (2010) Inhibition of cGMP phosphodiesterase 5 suppresses matrix metalloproteinase-2 production in pulmonary artery smooth muscle cells. Clin Exp Pharmacol Physiol 37:362–367PubMedCrossRef

25.

Takatsuki S, Calderbank M, Ivy DD (2012) Initial experience with tadalfil in pediatric pulmonary arterial hypertension. Pediatr Cardiol 33:683–688PubMedCrossRef

26.

Torres F, Gupta H, Soto F, et al (2011) Safety and efficacy of bosentan in combination with sildenafil in pulmonary arterial hypertension: the COMPASS-3 Study (abstract). In: ERS Annual Congress 2011

27.

Tudor A, Muşat A, Bari M et al (2005) Observations on peripheral microcirculation in young hypertensive patients. Rom J Intern Med 43:73–78PubMed

28.

U.S Food and Drug Administration (2012) FDA drug safety communication: FDA recommends against use of Revatio in children with pulmonary hypertension. http://www.fda.gov/Drugs/DrugSafety/ucm317123.htm. Accessed 11 Mar 2012

29.

Wirostko B, Trssler C, Hwang L et al (2012) Ocular safety of sildenafil citrate when administered chronically for pulmonary arterial hypertension: results from phase III, randomised, double-masked, placebo-controlled trial and open label extension. BMJ 344:e554PubMedCrossRef

30.

Wrishko RE, Dingemanse J, Yu A et al (2008) Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects. J Clin Pharmacol 48:610–618PubMedCrossRef

Title: Evolving Management of Pediatric Pulmonary Arterial Hypertension: Impact of Phosphodiesterase Inhibitors
Authors: Andrew James Wardle
Robert M. R. Tulloh
Publication date: 01-02-2013
Publisher: Springer-Verlag
Published in: Pediatric Cardiology / Issue 2/2013
Print ISSN: 0172-0643
Electronic ISSN: 1432-1971
DOI: https://doi.org/10.1007/s00246-012-0598-8

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Evolving Management of Pediatric Pulmonary Arterial Hypertension: Impact of Phosphodiesterase Inhibitors

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2013

Upcoming Events in Pediatric Cardiology

Caloric Intake During the Perioperative Period and Growth Failure in Infants With Congenital Heart Disease

Diagnostic Challenge in Desmin Cardiomyopathy With Transformation of Clinical Phenotypes

Tricuspid Regurgitation in Acute Phase of Kawasaki Disease Associated With Intensive Care Unit Admission

Do Predictors of Incomplete Kawasaki Disease Exist for Infants?

Is Race Associated With Morbidity and Mortality After Hospital Discharge Among Neonates Undergoing Heart Surgery?

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page